Mostrar el registro sencillo del ítem

dc.contributor.authorHernández, Gonzalo
dc.contributor.authorParedes, Irene
dc.contributor.authorMoran, Francisco
dc.contributor.authorBuj, Marcos
dc.contributor.authorColinas, Laura
dc.contributor.authorRodríguez, María Luisa
dc.contributor.authorVelasco, Alfonso
dc.contributor.authorRodríguez, Patricia
dc.contributor.authorPérez‑Pedrero, María José
dc.contributor.authorSuarez‑Sipmann, Fernando
dc.contributor.authorCanabal, Alfonso
dc.contributor.authorCuena, Rafael
dc.contributor.authorBlanch, Lluis
dc.contributor.authorRoca, Oriol
dc.date.accessioned2023-06-12T10:15:12Z
dc.date.available2023-06-12T10:15:12Z
dc.date.issued2022
dc.identifier.issn0342-4642spa
dc.identifier.urihttps://hdl.handle.net/10641/3398
dc.description.abstractPurpose High-flow nasal cannula (HFNC) oxygen therapy was noninferior to noninvasive ventilation (NIV) for preventing reintubation in a heterogeneous population at high-risk for extubation failure. However, outcomes might differ in certain subgroups of patients. Thus, we aimed to determine whether NIV with active humidification is superior to HFNC in preventing reintubation in patients with ≥ 4 risk factors (very high risk for extubation failure). Methods Randomized controlled trial in two intensive care units in Spain (June 2020‒June 2021). Patients ready for planned extubation with ≥ 4 of the following risk factors for reintubation were included: age > 65 years, Acute Physiology and Chronic Health Evaluation II score > 12 on extubation day, body mass index > 30, inadequate secretions management, difficult or prolonged weaning, ≥ 2 comorbidities, acute heart failure indicating mechanical ventilation, moderate-to-severe chronic obstructive pulmonary disease, airway patency problems, prolonged mechanical ventilation, or hypercapnia on finishing the spontaneous breathing trial. Patients were randomized to undergo NIV with active humidification or HFNC for 48 h after extubation. The primary outcome was reintubation rate within 7 days after extubation. Secondary outcomes included postextubation respiratory failure, respiratory infection, sepsis, multiorgan failure, length of stay, mortality, adverse events, and time to reintubation. Results Of 182 patients (mean age, 60 [standard deviation (SD), 15] years; 117 [64%] men), 92 received NIV and 90 HFNC. Reintubation was required in 21 (23.3%) patients receiving NIV vs 35 (38.8%) of those receiving HFNC (difference −15.5%; 95% confidence interval (CI) −28.3 to −1%). Hospital length of stay was lower in those patients treated with NIV (20 [12‒36.7] days vs 26.5 [15‒45] days, difference 6.5 [95%CI 0.5–21.1]). No additional differences in the other secondary outcomes were observed. Conclusions Among adult critically ill patients at very high-risk for extubation failure, NIV with active humidification was superior to HFNC for preventing reintubation.spa
dc.language.isoengspa
dc.publisherIntensive Care Medicinespa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectWeaningspa
dc.subjectReintubationspa
dc.subjectHigh-flow nasal cannulaspa
dc.subjectNoninvasive ventilationspa
dc.subjectActive humidificationspa
dc.titleEffect of postextubation noninvasive ventilation with active humidification vs high‑flow nasal cannula on reintubation in patients at very high risk for extubation failure: a randomized trial.spa
dc.typejournal articlespa
dc.type.hasVersionAMspa
dc.rights.accessRightsopen accessspa
dc.description.extent1227 KBspa
dc.identifier.doi10.1007/s00134-022-06919-3spa
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s00134-022-06919-3#change-historyspa


Ficheros en el ítem

FicherosTamañoFormatoVer
s00134-022-06919-3.pdf1.196MbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España